Vaccine Adjuvants Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product (Mineral Salt-based Adjuvant, Tensoactive Adjuvants, Adjuvant Emulsions, Liposome Adjuvants, Carbohydrate Adjuvants, Bacteria-derived Adjuvants, Virus-like Particles (VLP), Others), By Usage (Active Immunostimulants, Carriers, Vehicle Adjuvants), By Disease Type (Infectious Disease, Cancer), By Application (Research Applications, Commercial Applications), and Region

Vaccine Adjuvants Market size was valued at US$ 1.53 billion in 2023 and is poised to grow at a significant CAGR of 12.6% over 2024-2030. The market refers to the market for substances or compounds that are added to vaccines to enhance their immune response. Adjuvants play a crucial role in improving the effectiveness of vaccines by stimulating the immune system and boosting the body's immune response to the vaccine antigens. They are used to enhance the duration and intensity of the immune response, reduce the amount of antigen required per dose, and improve vaccine efficacy.

The driving factors in the market are the increasing prevalence of infectious diseases and the need for effective vaccines. With the emergence of new and re-emerging infectious diseases, there is a growing demand for vaccines that provide robust and long-lasting protection. Adjuvants can help in achieving this goal by enhancing the immune response and improving vaccine efficacy, thereby driving the market demand.

However, a significant challenge in the market is the regulatory complexities and safety concerns associated with adjuvants. The development and approval process for adjuvanted vaccines requires a thorough evaluation of their safety profiles and potential adverse effects. Regulatory authorities have stringent guidelines and criteria for the assessment and approval of adjuvants, which can be time-consuming and costly. Additionally, there is a need for continuous monitoring and surveillance of vaccine safety to address any potential risks associated with adjuvants. The market is driven by the increasing prevalence of infectious diseases and the need for effective vaccines. However, regulatory complexities and safety concerns pose challenges to the market's growth and development.

Vaccine Adjuvants Market Key Developments

• In January 2023, Dynavax Technologies Corporation and Sanofi Pasteur announced a collaboration to develop and commercialize a new adjuvant for use in Sanofi Pasteur's influenza vaccine candidates. The adjuvant, called CpG 1018, is a synthetic Toll-like receptor 9 agonist that has been shown to boost the immune response to vaccines in clinical trials. The collaboration is expected to accelerate the development and commercialization of a new influenza vaccine that is more effective and affordable than current vaccines.
• In February 2023, Adjuvance Technologies Inc., announced the launch of its new adjuvant, called ATX-M102. ATX-M102 is a saponin-based adjuvant that has been shown to be safe and effective in clinical trials. The adjuvant is designed to be used in a variety of different vaccines, including vaccines against infectious diseases, cancer, and allergies.